Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to ...

Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...

Investing.com -- Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during ...

This is where Allurion’s unique approach comes into play. Previous studies have demonstrated that patients using the Allurion Gastric Balloon in combination with the Allurion Virtual Care Suite ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

U.S. stock futures fell on Friday following a 25 basis point rate hike by the Bank of Japan. Futures of all four indices declined.

The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM gastric balloon for weight loss, the Allurion ...

Texas Instruments reported lower profit and revenue in the fourth quarter, while its first-quarter outlook missed expectations. The chipmaker reported a profit of $1.21 billion on revenue of $4.01 ...

Shantanu Gaur, the founder and chief executive of Allurion, said the goal of the study would be to prove that combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy would ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.